234 related articles for article (PubMed ID: 25740072)
1. Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.
Ramya LN; Pulicherla KK
Pathol Oncol Res; 2015 Sep; 21(4):909-20. PubMed ID: 25740072
[TBL] [Abstract][Full Text] [Related]
2. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
3. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
[TBL] [Abstract][Full Text] [Related]
4. Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer.
Cantor JR; Panayiotou V; Agnello G; Georgiou G; Stone EM
Methods Enzymol; 2012; 502():291-319. PubMed ID: 22208990
[TBL] [Abstract][Full Text] [Related]
5. Cloning, expression and characterisation of Erwinia carotovora L-asparaginase.
Kotzia GA; Labrou NE
J Biotechnol; 2005 Oct; 119(4):309-23. PubMed ID: 15951039
[TBL] [Abstract][Full Text] [Related]
6. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Ardalan N; Mirzaie S; Sepahi AA; Khavari-Nejad RA
Med Hypotheses; 2018 Mar; 112():7-17. PubMed ID: 29447943
[TBL] [Abstract][Full Text] [Related]
7. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
8. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
9. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
10. A Structural In Silico Analysis of the Immunogenicity of L-Asparaginase from
Andrade KCR; Homem-de-Mello M; Motta JA; Borges MG; de Abreu JAC; de Souza PM; Pessoa A; Pappas GJ; de Oliveira Magalhães P
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732010
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional insights into Erwinia carotovora L-asparaginase.
Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of glutaminase-free L-asparaginase from Pectobacterium carotovorum MTCC 1428.
Kumar S; Venkata Dasu V; Pakshirajan K
Bioresour Technol; 2011 Jan; 102(2):2077-82. PubMed ID: 20832300
[TBL] [Abstract][Full Text] [Related]
13. [Oligomerization of L-asparaginase from Erwinia carotovora].
Mezentsev IuV; Mol'nar AA; Gnedenko OV; Krasotkina IuV; Sokolov NN; Ivanov AS
Biomed Khim; 2006; 52(3):258-71. PubMed ID: 16898584
[TBL] [Abstract][Full Text] [Related]
14. Studies on pH and thermal stability of novel purified L-asparaginase from Pectobacterium carotojorum MTCC 1428.
Kumar S; Dasu VV; Pakshirajan K
Mikrobiologiia; 2011; 80(3):349-55. PubMed ID: 21861371
[TBL] [Abstract][Full Text] [Related]
15. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
16. Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach.
Yari M; Eslami M; Ghoshoon MB; Nezafat N; Ghasemi Y
Mol Biol Rep; 2019 Oct; 46(5):4751-4761. PubMed ID: 31290058
[TBL] [Abstract][Full Text] [Related]
17. One-step purification and kinetic properties of the recombinant L-asparaginase from Erwinia carotovora.
Krasotkina J; Borisova AA; Gervaziev YV; Sokolov NN
Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):215-21. PubMed ID: 15032742
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional role of Gly281 in L-asparaginase from Erwinia carotovora.
Kotzia GA; Labrou NE
Protein Pept Lett; 2013 Dec; 20(12):1302-7. PubMed ID: 24261975
[TBL] [Abstract][Full Text] [Related]
20. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
